DiaMedica Therapeutics Inc. (DMAC) vs Bright Minds Biosciences Inc. (DRUG)
A side-by-side comparison of DiaMedica Therapeutics Inc. and Bright Minds Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DMAC
DiaMedica Therapeutics Inc.
$8.26HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
DRUG
Bright Minds Biosciences Inc.
$48.58HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — DMAC vs DRUG
growth of $100 · dividends reinvested · last 6yDMAC -12.6% (-2.2%/yr)DRUG +84.4% (+10.7%/yr)DRUG compounded faster over this window
DMAC DRUG
DMAC vs DRUG: by the numbers
- •DRUG is the larger company ($475M vs $445M market cap).
Metrics side by side
Valuation
| Metric | DMAC | DRUG |
|---|---|---|
| P/B ratio | 11.61 | 2.19 |
Profitability
| Metric | DMAC | DRUG |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -97.92% | -8.21% |
| ROIC | -100.87% | -13.15% |
Growth (annualized)
| Metric | DMAC | DRUG |
|---|---|---|
| Total return CAGR (5Y) | 16.41% | 6.76% |
Frequently asked
- How have DMAC and DRUG total returns compared?
- Over the past 5 years, DMAC delivered 16.41% and DRUG delivered 6.76% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.